Allergens for Subcutaneous Immune Therapy
Allergens for Subcutaneous Immune Therapy
Therapy allergens are used for Allergen immunotherapy (AIT) in order to restore tolerance to the respective allergen.
In the case of the subcutaneous immune therapy (also called subcutaneous hyposensitisation), the allergen extract is injected into the skin in partly increasing doses over a longer period of time (as a rule several years).
Therapy allergens for the subcutaneous immune therapy are available for the following allergen classes:
- Tree Pollen
- Grass-, Cereal and Herbal Pollen
- House Dust Mites
- Insect Venoms
top
Tree Pollen
Tree Pollen
Approved Allergens for Subcutaneous Immune Therapy against Tree Pollen
Disclaimer
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 528 in BAnz AT 25.04.2025 B4.
Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
top
Grass- / Cereal- / Herbal pollen
Grass- / Cereal- / Herbal pollen
Approved Allergens for Subcutaneous Immune Therapy against against Grass-, Cereal- and Herbal Pollen
Disclaimer
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 528 in BAnz AT 25.04.2025 B4.
Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
House Dust Mites
House Dust Mites
Approved Allergens for Subcutaneous Immune Therapy against House Dust Mites
Name
|
Marketing Authorisation Holder
|
License Number
|
License Date
|
Further Information
|
ALK-depot SQ 503 Derm. pteron. 100.000 SQ-E/ml
|
ALK-Abelló Arzneimittel GmbH
|
151a/90c |
25.10.1990 |
PharmNet.Bund
|
ALK-depot SQ 510 Milbenmischung 10.000 SQ-E/ml
|
ALK-Abelló Arzneimittel GmbH
|
150a/90b |
25.10.1990 |
PharmNet.Bund
|
ALK-depot SQ 503 Derm. pteron. 100 SQ-E/ml
|
ALK-Abelló Arzneimittel GmbH
|
151a/90 |
25.10.1990 |
PharmNet.Bund
|
ALK-depot SQ 510 Milbenmischung 1000 SQ-E/ml
|
ALK-Abelló Arzneimittel GmbH
|
150a/90a |
25.10.1990 |
PharmNet.Bund
|
ALK-depot SQ 503 Derm. pteron. 1000 SQ-E/ml
|
ALK-Abelló Arzneimittel GmbH
|
151a/90a |
25.10.1990 |
PharmNet.Bund
|
ALK-depot SQ 510 Milbenmischung 100 SQ-E/ml
|
ALK-Abelló Arzneimittel GmbH
|
150a/90 |
25.10.1990 |
PharmNet.Bund
|
ALK-depot SQ 510 Milbenmischung 100.000 SQ-E/ml
|
ALK-Abelló Arzneimittel GmbH
|
150a/90c |
25.10.1990 |
PharmNet.Bund
|
ALK-depot SQ 503 Derm. pteron. 10.000 SQ-E/ml
|
ALK-Abelló Arzneimittel GmbH
|
151a/90b |
25.10.1990 |
PharmNet.Bund
|
Novo-Helisen 708 Milbe I (Dermatophagoides farinae) 50%, 725 Milbe II (Dermatophagoides pteronyssinus) 50% Stärke 3
|
Allergopharma GmbH & Co. KG
|
576a/91a |
14.10.1992 |
PharmNet.Bund
|
Novo-Helisen 708 Milbe I (Dermatophagoides farinae) 50%, 725 Milbe II (Dermatophagoides pteronyssinus) 50% Stärke 1
|
Allergopharma GmbH & Co. KG
|
576a/91c |
14.10.1992 |
PharmNet.Bund
|
Novo-Helisen 708 Milbe I (Dermatophagoides farinae) 50%, 725 Milbe II (Dermatophagoides pteronyssinus) 50% Stärke 2
|
Allergopharma GmbH & Co. KG
|
576a/91b |
14.10.1992 |
PharmNet.Bund
|
Novo-Helisen 725 Milbe II (Dermatophagoides pteronyssinus), 100% Stärke 1
|
Allergopharma GmbH & Co. KG
|
575a/91c |
14.10.1992 |
PharmNet.Bund
|
Novo-Helisen 725 Milbe II (Dermatophagoides pteronyssinus), 100% Stärke 2
|
Allergopharma GmbH & Co. KG
|
575a/91b |
14.10.1992 |
PharmNet.Bund
|
Novo-Helisen 725 Milbe II (Dermatophagoides pteronyssinus), 100% Stärke 3
|
Allergopharma GmbH & Co. KG
|
575a/91a |
14.10.1992 |
PharmNet.Bund
|
Novo-Helisen 708 Milbe I (Dermatophagoides farinae), 100% Stärke 3
|
Allergopharma GmbH & Co. KG
|
574a/91a |
14.10.1992 |
PharmNet.Bund
|
Novo-Helisen 708 Milbe I (Dermatophagoides farinae), 100% Stärke 1
|
Allergopharma GmbH & Co. KG
|
574a/91c |
14.10.1992 |
PharmNet.Bund
|
Novo-Helisen 708 Milbe I (Dermatophagoides farinae), 100% Stärke 2
|
Allergopharma GmbH & Co. KG
|
574a/91b |
14.10.1992 |
PharmNet.Bund
|
Depigoid Milbe D. pteronyssinus 100 DPP/ml
|
Leti Pharma GmbH
|
PEI.H.03067.02.1 |
22.12.2004 |
|
Depigoid Milben-Mix 10 DPP/ml
|
Leti Pharma GmbH
|
PEI.H.03068.01.1 |
22.12.2004 |
|
Depigoid Milbe D. pteronyssinus 10 DPP/ml
|
Leti Pharma GmbH
|
PEI.H.03067.01.1 |
22.12.2004 |
|
Depigoid Milben-Mix 100 DPP/ml
|
Leti Pharma GmbH
|
PEI.H.03068.02.1 |
22.12.2004 |
|
Disclaimer
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 528 in BAnz AT 25.04.2025 B4.
Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Insect Venoms
Insect Venoms
Approved Allergens for Subcutaneous Immune Therapy against Insect Venoms
Name
|
Marketing Authorisation Holder
|
License Number
|
License Date
|
Further Information
|
ALK-depot SQ 801 Bienengift 10.000 SQ-E/ml
|
ALK-Abelló Arzneimittel GmbH
|
112a/91c |
05.02.1992 |
PharmNet.Bund
|
ALK-depot SQ 801 Bienengift 100 SQ-E/ml
|
ALK-Abelló Arzneimittel GmbH
|
112a/91a |
05.02.1992 |
PharmNet.Bund
|
ALK-depot SQ 801 Bienengift 100.000 SQ-E/ml
|
ALK-Abelló Arzneimittel GmbH
|
112a/91d |
05.02.1992 |
PharmNet.Bund
|
ALK-depot SQ 801 Bienengift 1000 SQ-E/ml
|
ALK-Abelló Arzneimittel GmbH
|
112a/91b |
05.02.1992 |
PharmNet.Bund
|
ALK-depot SQ 802 Wespengift 10.000 SQ-E/ml
|
ALK-Abelló Arzneimittel GmbH
|
113a/91c |
05.02.1992 |
PharmNet.Bund
|
ALK-depot SQ 802 Wespengift 100 SQ-E/ml
|
ALK-Abelló Arzneimittel GmbH
|
113a/91a |
05.02.1992 |
PharmNet.Bund
|
ALK-depot SQ 802 Wespengift 100.000 SQ-E/ml
|
ALK-Abelló Arzneimittel GmbH
|
113a/91d |
05.02.1992 |
PharmNet.Bund
|
ALK-depot SQ 802 Wespengift 1000 SQ-E/ml
|
ALK-Abelló Arzneimittel GmbH
|
113a/91b |
05.02.1992 |
PharmNet.Bund
|
ALK-lyophilisiert SQ 801 Bienengift
|
ALK-Abelló Arzneimittel GmbH
|
62a/82e |
13.10.1982 |
PharmNet.Bund
|
ALK-lyophilisiert SQ 802 Wespengift
|
ALK-Abelló Arzneimittel GmbH
|
63a/82e |
13.10.1982 |
PharmNet.Bund
|
Venomenhal Biene
|
HAL Allergy B.V.
|
191a/96b |
23.10.1997 |
PharmNet.Bund
|
Venomenhal Wespe
|
HAL Allergy B.V.
|
192a/96b |
23.10.1997 |
PharmNet.Bund
|
Venomil Biene
|
Bencard Allergie GmbH
|
120a/80 |
10.10.1980 |
PharmNet.Bund
|
Venomil Wespe
|
Bencard Allergie GmbH
|
121a/80 |
10.10.1980 |
PharmNet.Bund
|
Disclaimer
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 528 in BAnz AT 25.04.2025 B4.
Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.